If You Invested in QHSLab Inc (USAQ)

QHSLab, Inc. (OTCQB: USAQ) is a healthcare technology and medical device company focused on digital health, preventive screening, and point-of-care diagnostics for primary care. The company describes itself as a digital health infrastructure and digital medicine provider that supports primary care practices with screening, assessment, workflow, and monitoring tools. Its solutions are designed to help physicians identify and manage underdiagnosed chronic, behavioral, and cognitive conditions while documenting care in a way that supports reimbursement and value-based care models.

According to company disclosures, QHSLab’s platform enables care that occurs outside the exam room, including screening, monitoring, education, and follow-up, to be delivered in a scalable and documented manner across multiple underdiagnosed conditions. The company emphasizes tools that are reimbursable under existing CPT codes, allowing primary care providers to integrate digital assessments into routine practice while capturing billable services.

Business focus and core offerings

QHSLab states that it provides digital healthcare solutions and point-of-care rapid-response diagnostic tests to primary care physicians. Its digital tools use data-driven assessments to evaluate patient responses and support clinical decision-making. The company reports that its products and services are intended to improve patient monitoring and medical care while also increasing physician revenues.

The company’s offerings include:

• Preventive screening and assessment tools for chronic, behavioral, and cognitive conditions in primary care settings.
• Workflow solutions that integrate assessments into practice operations, supporting documentation, coding, and reimbursement.
• Point-of-care diagnostic tests marketed and sold for use in primary care practices.
• Integrated Service Program (ISP), which the company identifies as a revenue-generating service line within its digital medicine and clinical services model.
• Allergy diagnostics and immunotherapy-related offerings, referenced in company revenue breakdowns and partnership announcements.

Digital medicine, population health, and value-based care

QHSLab describes itself as a digital health company advancing personalized medicine through population health screening and point-of-care diagnostic tools in primary care. Its communications highlight a focus on mental health, preventive screening, AI-supported care, and value-based clinical technologies. The company reports that its tools help practices identify, document, and manage underdiagnosed chronic and behavioral conditions efficiently and in a way that supports practice revenue.

In its public materials, QHSLab links its digital assessments to value-based care and population health performance. It notes that certain tools are designed to support risk adjustment, neurocognitive and behavioral health coding, and documentation that aligns with reimbursement frameworks. The company also references research and clinical validation efforts intended to demonstrate both clinical effectiveness and economic benefits for primary care practices.

Example product: Q-Cog™ cognitive assessment

QHSLab has announced the launch of Q-Cog™, which it describes as a comprehensive, cloud-based cognitive assessment for primary care. According to the company, Q-Cog™ combines validated cognitive, behavioral, and functional screening within a single digital workflow to help identify Mild Cognitive Impairment (MCI) and dementia-related risks earlier in the disease process.

The company states that Q-Cog™ is designed to:

• Help primary care clinicians meet cognitive screening guidelines.
• Support risk adjustment and reimbursement under neurocognitive and behavioral health codes.
• Enable early identification of at-risk individuals and facilitate timely follow-up, including telemedicine referrals.
• Contribute data that supports value-based care and population health metrics.

QHSLab reports that an initial real-world pilot of Q-Cog™ among older patients identified a substantial proportion with high-risk cognitive scores, which the company cites as evidence of unmet need and the potential impact of structured digital screening in primary care.

Research, validation, and clinical focus areas

The company highlights peer-reviewed research and clinical studies as part of its strategy. It reports publications that validate the clinical and economic impact of its digital assessment tools in primary care, including:

• A longitudinal study on help-seeking behaviors in allergic rhinitis and mental health, which the company notes links early help-seeking with better mental health outcomes over time.
• Development and validation of the Q-Scale, described as a tool to predict healthcare overutilization by assessing psychosocial, affective, and somatic factors, enabling providers to identify high-risk patients and plan targeted interventions.

QHSLab also references ongoing work in mental health, chronic pain, and allergic rhinitis through digital health journeys and clinical collaborations. The company states that its tools are designed to support early detection, cognitive profiling, risk stratification, and personalized care in real-world primary care environments.

Primary care and partnership orientation

Across its disclosures, QHSLab consistently positions primary care practices as its core customer base. Its digital health and diagnostic offerings are framed as tools that can be embedded into routine primary care workflows to enhance patient outcomes and practice economics. The company has announced a co-marketing partnership with Town Total Compounding, under which QHSLab’s Integrated Service Program is introduced to a network of primary care practices alongside personalized prescription therapies.

Through this type of collaboration, QHSLab aims to align digital assessments with individualized pharmacologic treatments in areas such as GLP-1 therapies, hormone replacement, allergen immunotherapy, pain management, and dermatological care. The company characterizes this approach as a way to support organic growth and expand access to digital health capabilities without relying on equity dilution.

Capital structure and regulatory status

QHSLab, Inc. is incorporated in Nevada and reports its common stock, par value $0.0001 per share, under the trading symbol USAQ. The company’s common stock is quoted on the OTCQB market, and its securities are registered under Section 12(g) of the Securities Exchange Act of 1934, as reflected in its Form 8-K filings. These filings also describe private placements of common stock and warrants, repurchases and conversions of convertible notes, and other capital structure developments.

In its public communications, the company has emphasized efforts to simplify its balance sheet, repurchase legacy convertible debt, and complete equity financings that it characterizes as strengthening liquidity and reducing potential dilution. QHSLab has also furnished corporate presentations, shareholder letters, and press releases through Form 8-Ks as part of its investor communications.

Financial profile and revenue mix (high-level)

QHSLab’s public updates describe revenue contributions from multiple categories, including Integrated Service Program services, allergy diagnostic kits, immunotherapy, clinical study-related revenue, subscriptions, shipping and handling, and training and other services. The company has highlighted year-over-year revenue growth and improvements in gross margin in certain reported periods, attributing these trends to product mix and increased traction of higher-margin services.

While specific financial figures are time-sensitive and subject to change, these disclosures illustrate that QHSLab generates revenue from both digital services and physical diagnostic products, with an emphasis on recurring assessments and integrated clinical programs in primary care.

Regulatory filings and disclosures

QHSLab files periodic and current reports with the U.S. Securities and Exchange Commission, including Form 10-Q for quarterly results, Form 10-K for annual results, and multiple Form 8-K reports describing material events such as debt repurchases, private placements, product launches, and investor communications. The company also notes in its filings that it uses its corporate website, press releases, and social media channels as additional means of public disclosure.

How QHSLab positions its value to providers

Across its news releases and descriptions, QHSLab presents its value proposition to primary care providers as combining clinical-grade digital assessments with reimbursement-aligned workflows. The company states that its tools are intended to:

• Support early detection and risk stratification in mental health, cognitive decline, allergic conditions, and other chronic issues.
• Integrate into routine visits and digital journeys to personalize care plans.
• Enable CPT-coded, reimbursable services that can expand practice revenue.
• Improve resource utilization by identifying high-risk patients and reducing unnecessary visits.

For investors and analysts, these elements frame QHSLab as a healthcare technology and medical device company operating at the intersection of digital medicine, primary care workflows, and value-based reimbursement.